Artiva Biotherapeutics, Inc. (ARTV) Stock Price & Analysis
Artiva Biotherapeutics, Inc. (ARTV) rose 6.91% to USD 7.27 as of June 10, 2026 at 00:27 UTC, according to Nexqual real-time market data.
ARTV last closed at USD 6.8; the session ranged USD 6.74–7.42 on volume of 968,062 shares. Market capitalization is $353.24M, with a 52-week range of USD 1.47–14.53 (NGM). Source: Nexqual, June 10, 2026 at 00:27 UTC.
Key Statistics (as of June 10, 2026 at 00:27 UTC)
| Price | USD 7.27 |
|---|---|
| Change | ▲ 6.91% (up) |
| Previous Close | USD 6.8 |
| Open | USD 6.77 |
| Day Range | USD 6.74 – 7.42 |
| 52-Week Range | USD 1.47 – 14.53 |
| Volume | 968,062 shares |
| Market Cap | $353.24M |
| Exchange | NGM |
Technical Analysis (ARTV)
Nexqual's technical model rates ARTV "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 00:27 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 38.86 (neutral) |
| vs SMA50 | Below (USD 8.97) |
| MACD | -0.68 (negative) |
Analyst Ratings (ARTV)
Wall Street analysts rate ARTV "Strong Buy" based on 5 analysts, with a mean price target of USD 35.8 (range USD 23–41), per Nexqual as of June 10, 2026 at 00:27 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 35.8 |
| High Target | USD 41 |
| Low Target | USD 23 |
| Buy / Hold / Sell | 6 / 0 / 0 |
Earnings (ARTV)
| EPS Estimate | USD -0.64 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.95 vs est -0.84 ▼ miss |
| 2025-12-31 | USD -0.84 vs est -0.8 ▼ miss |
| 2025-09-30 | USD -0.88 vs est -0.8 ▼ miss |
| 2025-06-30 | USD -0.87 vs est -0.77 ▼ miss |
Source: Nexqual, June 10, 2026 at 00:27 UTC.
Financials & Fundamentals (ARTV)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -67.86% |
| Debt / Equity | 11.68 |
| Current Ratio | 8.16 |
| Total Cash | $86.78M |
| Total Debt | $10.26M |
| Free Cash Flow | $-48.96M |
Source: Nexqual, June 10, 2026 at 00:27 UTC.
Financial Health Score (ARTV)
Nexqual rates Artiva Biotherapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 00:27 UTC.
| Growth | Critical — Revenue -100% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $87M cash vs $10M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$78M |
| Efficiency | Critical — ROE -68%, ROA -38.7% |
Ownership (ARTV)
| Insider Ownership | +14.14% |
|---|---|
| Institutional Ownership | +48.20% |
| Shares Outstanding | 48.59M |
| Float | 6.00M |
| Short % of Float | +3.02% |
Source: Nexqual, June 10, 2026 at 00:27 UTC.
Leadership (ARTV)
Artiva Biotherapeutics, Inc. is led by Fred Aslan (age 50), CEO, Principal Financial & Accounting Officer and Director, per Nexqual as of June 10, 2026 at 00:27 UTC.
| CEO, Principal Financial & Accounting Officer and Director | Fred Aslan (age 50) |
|---|---|
| President and Head of Research & Development | Gines Diego Miralles (age 62) |
| Chief Operating Officer | Jennifer Kinsbruner Bush Esq. (age 50) |
| Vice President of Corporate Development | Nicholas Veomett |
| Senior Vice President of Research & Early Development | Heather Raymon (age 60) |
Major Backers & Investors (ARTV)
Notable institutional backers of Artiva Biotherapeutics, Inc. include RA Capital Management, L.P., 5AM Venture Management, LLC, Venrock Adviser, LLC, according to Nexqual as of June 10, 2026 at 00:27 UTC.
Active Investors
| Investor | Stake |
|---|---|
| RA Capital Management, L.P. | 39.87% |
| 5AM Venture Management, LLC | 9.52% |
| Venrock Adviser, LLC | 6.51% |
| venBio Partners LLC | 2.15% |
| Franklin Resources, Inc. | 2.11% |
| Revelation Capital Management, LLC | 1.21% |
| Wellington Management | 0.79% |
| Franklin Strategic Series-FRANKLIN BIOTECHNOLOGY DISCOVERY FUND | 0.78% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 1.68% |
| BlackRock | 0.9% |
Source: Nexqual, June 10, 2026 at 00:27 UTC.
From Artiva Biotherapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-10)
Key Strengths & Strategy (as disclosed to the SEC)
- Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers.
- Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma.
- The company also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ALMS | Alumis Inc. | USD 20.01 | ▲ 4.98% |
| KYTX | Kyverna Therapeutics, Inc. | USD 7.85 | ▲ 5.09% |
| ANRO | Alto Neuroscience, Inc. | USD 21.15 | ▲ 15.83% |
| QTTB | Q32 Bio Inc. | USD 11.89 | ▼ 9.31% |
| PEPG | PepGen Inc. | USD 1.38 | ▼ 2.13% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:27 UTC. This page is informational and not investment advice.